Scholarlink

Purpose <p>This study aimed to develop a polyvinylpyrrolidone (PVP)-based amorphous solid dispersion (ASD) formulation to prevent the crystallization of tegoprazan (TPZ) during long-term storage and to establish a foundation for commercial tablet manufacturing.</p> Methods <p>The solubility of TPZ-ASD was evaluated in water and buffer solutions. Flowability was assessed using Carr’s Index and the Hausner ratio (HR), and the results were compared with those of amorphous TPZ (TPZ-Am) and crystalline TPZ (TPZ-Cr). Recrystallization during storage was monitored using differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) under both long-term (25 ℃, 60% relative humidity [RH]) and accelerated (40 ℃, 75% RH) conditions. The dissolution profiles of tablets prepared with TPZ-ASD were compared with those of a commercial product.</p> Results <p>TPZ-ASD exhibited approximately a 20-fold increase in water solubility compared to TPZ-Cr and showed enhanced solubility across all tested pH conditions. Carr’s Index and HR value indicated that TPZ-ASD had better flowability than both TPZ-Cr and TPZ-Am. Stability analyses using DSC and PXRD revealed no recrystallization for up to 24 months (raw material) and 12 months (tablet) under long-term storage conditions and for 6 months under accelerated conditions, respectively. A human pharmacokinetic study demonstrated that the TPZ-ASD tablet was bioequivalent to the commercial product.</p> Conclusion <p>The PVP-based solid dispersion effectively inhibited TPZ crystallization over an extended period. Furthermore, the TPZ-ASD formulation proved successfully applicable to the manufacturing process, and the commercial potential of this technology was identified in a Phase 1 clinical pharmacokinetics study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preparation and evaluation of tegoprazan tablets using long-term crystallization-suppressing solid dispersion technology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月5日

查看全文
  • Shinwoog Kang,
  • Yong-Hoon Won,
  • Ji-Hyun Yang,
  • Jimi Byeon,
  • Sangkil Lee

摘要

Purpose

This study aimed to develop a polyvinylpyrrolidone (PVP)-based amorphous solid dispersion (ASD) formulation to prevent the crystallization of tegoprazan (TPZ) during long-term storage and to establish a foundation for commercial tablet manufacturing.

Methods

The solubility of TPZ-ASD was evaluated in water and buffer solutions. Flowability was assessed using Carr’s Index and the Hausner ratio (HR), and the results were compared with those of amorphous TPZ (TPZ-Am) and crystalline TPZ (TPZ-Cr). Recrystallization during storage was monitored using differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) under both long-term (25 ℃, 60% relative humidity [RH]) and accelerated (40 ℃, 75% RH) conditions. The dissolution profiles of tablets prepared with TPZ-ASD were compared with those of a commercial product.

Results

TPZ-ASD exhibited approximately a 20-fold increase in water solubility compared to TPZ-Cr and showed enhanced solubility across all tested pH conditions. Carr’s Index and HR value indicated that TPZ-ASD had better flowability than both TPZ-Cr and TPZ-Am. Stability analyses using DSC and PXRD revealed no recrystallization for up to 24 months (raw material) and 12 months (tablet) under long-term storage conditions and for 6 months under accelerated conditions, respectively. A human pharmacokinetic study demonstrated that the TPZ-ASD tablet was bioequivalent to the commercial product.

Conclusion

The PVP-based solid dispersion effectively inhibited TPZ crystallization over an extended period. Furthermore, the TPZ-ASD formulation proved successfully applicable to the manufacturing process, and the commercial potential of this technology was identified in a Phase 1 clinical pharmacokinetics study.